Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Rev. psiquiatr. clín. (São Paulo) ; 45(1): 7-11, Jan.-Feb. 2018. tab
Article in English | LILACS | ID: biblio-903050

ABSTRACT

Abstract Background The identification of facial emotions is a key skill as it promotes rapid and accurate recognition of emotions and enables better communication and greater social adaptation. More recent studies have suggested that impaired social interactions may be related to deficits in social cognition and therefore in the recognition of facial expressions, contributing to social disturbance among individuals with borderline personality disorder (BPD). Objective To present the results of an empirical study assessing the recognition of facial emotion expressions in women with BPD, having as reference a group of healthy women from the general population. Methods The subjects (40 female with BPD and 40 controls) were assessed with a dynamic task on a computer screen for recognition of facial expressions of emotion. Results The BPD group had a lower accuracy in perceiving emotions of fear and surprise and slowness in recognising happiness. Logistic regression analyses also identified an association between BPD and higher sensitivity in the recognition of anger. Discussion Women with BPD made more mistakes in the recognition of negative emotions, which can bias the behaviour and regulation of affective states, favouring in turn the emergence of some typical symptoms associated with BPD.

2.
Rev. psiquiatr. clín. (São Paulo) ; 45(1): 22-24, Jan.-Feb. 2018. tab
Article in English | LILACS | ID: biblio-1438577

ABSTRACT

Background Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major depressive disorder. Objectives To investigate if the experiment had any long-lasting effects on patients Methods Eight patients were interviewed 4 to 7 years after ayahuasca intake. Results Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion To the best of our knowledge, this is the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed to further explore the antidepressive and anxiolytic effects of ayahuasca.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Banisteriopsis , Depression/drug therapy , Anxiety/drug therapy , Follow-Up Studies , Treatment Outcome , Banisteriopsis/adverse effects , Qualitative Research
3.
Rev. psiquiatr. clín. (São Paulo) ; 44(1): 10-19, Jan.-Feb. 2017. tab
Article in English | LILACS | ID: biblio-845829

ABSTRACT

Abstract Background DSM-5 introduced some modifications on Posttraumatic Stress Disorder (PTSD) criteria. The instruments developed for the assessment of aspects related to PTSD needed a reformulation, as was the case of the Posttraumatic Stress Disorder Checklist (PCL). Objectives To present the process of transcultural adaptation of the three forms of the PCL-5 to Brazilian Portuguese, as well as its face validity. Methods The procedure involved independent translations, a synthesis version, back translation by an independent translator, evaluation by the original author, analysis by an expert committee, and a pretesting study (10 subjects with/without experience of a traumatic situation). The last two steps formed the face validity procedure. Results The synthesis version was approved by the original author and the agreement percentage by the expert committee was excellent, with only two items showing < 90%. The pretesting study showed that the Brazilian version was well understood and linguistically and culturally accepted by the participants, which did not make significant suggestions for changes. Discussion Transcultural adaptation of the PCL-5 for Brazilian Portuguese followed a rigid and standardized procedure. Therefore, after having its face validity assessed by an expert committee and by the target population, it is apt to be used.

6.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 32(2): 173-180, jun. 2010. tab
Article in Portuguese | LILACS | ID: lil-553994

ABSTRACT

OBJETIVO: Avaliar as relações entre o uso agudo e crônico de cannabis e alterações do humor. MÉTODO: Os artigos foram selecionados por meio de busca eletrônica no indexador PubMed. Capítulos de livros e as listas de referências dos artigos selecionados também foram revisados. RESULTADOS: Observam-se elevados índices de comorbidade entre abuso/dependência de cannabis e transtornos afetivos em estudos transversais e em amostras clínicas. Estudos longitudinais indicam que, em longo prazo, o uso mais intenso de cannabis está relacionado com um risco maior de desenvolvimento de doença bipolar e, talvez, depressão maior em indivíduos inicialmente sem quadros afetivos; porém, os mesmos não encontraram maior risco de uso de cannabis entre aqueles com mania ou depressão sem esta comorbidade. Outra importante observação é que o uso de substâncias psicoativas em bipolares pode estar associado a uma série de características negativas, como dificuldade na recuperação dos sintomas afetivos, maior número de internações, piora na adesão ao tratamento, risco aumentado de suicídio, agressividade e a uma pobre resposta ao lítio. Tratamentos psicossociais e farmacológicos são indicados para o manejo da comorbidade entre cannabis e transtornos afetivos. CONCLUSÃO: As relações entre o uso de cannabis e alterações do humor são observadas tanto epidemiologicamente quanto nos contextos clínicos.


OBJECTIVE: Evaluate the relationship between acute and chronic use of cannabis and mood changes. METHOD: Articles were selected by electronic search in PubMed. Chapters in books and reference lists of selected articles were also reviewed. As the research did not involve humans, there was no evaluation by a Research Ethics Committee. RESULTS: High rates of comorbidity between use/abuse/dependence of cannabis and affective disorders in longitudinal studies and in clinical samples were observed. Longitudinal studies indicate that, in long-term, the higher use of cannabis is associated with an increased risk of developing bipolar disorder, and probably, major depression in subjects initially without affective disorder, but was not found increased risk of cannabis use among those initially only with mania or depression. Another important observation is that substance abuse in bipolar patients may be associated with a number of negative characteristics, such as difficulty in recovering the affective symptoms, more hospitalizations, poor compliance with treatment, increased risk of suicide, aggression and a poor response to lithium. Psychosocial and pharmacological treatments are indicated for the management of comorbidity between cannabis and affective disorders. CONCLUSION: The relationship between cannabis use and mood changes are observed both in the epidemiological research and in the clinical settings.


Subject(s)
Humans , Cannabis/adverse effects , Depression/chemically induced , Marijuana Abuse/complications , Mood Disorders/chemically induced , Bipolar Disorder/chemically induced , Bipolar Disorder/psychology , Depression/diagnosis , Dose-Response Relationship, Drug , Marijuana Smoking/psychology , Mood Disorders/diagnosis
7.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 32(1): 56-61, Mar. 2010. tab, ilus
Article in English | LILACS | ID: lil-541140

ABSTRACT

OBJECTIVE: The last decade has seen increasing evidence of dysfunctions in the endogenous cannabinoid system in schizophrenia and of its relationship with the typical cognitive impairment of the disorder. Studies in animal models, healthy volunteers, and psychotic patients clearly suggest an antipsychotic-like effect of cannabidiol. This study investigated the effects of cannabidiol on selective attention in 28 schizophrenic patients using the Stroop Color Word Test and on these patients' electrodermal responsiveness to auditive stimuli. METHOD: The subjects attended two experimental sessions, the first one without the administration of drugs. In the second session the subjects were divided into three groups that received either a single dose of cannabidiol 300mg or cannabidiol 600mg or placebo. RESULTS: The three groups did not differ significantly with respect to electrodermal measures in the two experimental sessions. When the first and second sessions were compared improved performance was found in all three groups, with patients who received placebo and cannabidiol 300mg performing better than those who received cannabidiol 600mg. CONCLUSION: The single, acute administration of cannabidiol seems to have no beneficial effects on the performance of schizophrenic patients in the Stroop Color Word Test, although the hypothesis that chronic administration may lead to improvement cannot be disregarded.


OBJETIVO: Descobertas relativas a possíveis disfunções do sistema canabinóide endógeno na esquizofrenia e sua relação com o prejuízo cognitivo característico da doença têm aumentado durante a última década. Estudos com modelos animais, voluntários saudáveis e pacientes psicóticos sugerem claramente que o canabidiol possui efeitos antipsicóticos. Este estudo investigou os efeitos do canabidiol sobre a atenção seletiva por meio do Stroop Color Word Test e a responsividade eletrodérmica a estímulos auditivos em 28 pacientes com esquizofrenia. MÉTODO: Duas sessões experimentais foram realizadas, a primeira sem a administração de drogas. Na segunda sessão, os sujeitos foram divididos em três grupos que receberam dose única de canabidiol 300mg, canabidiol 600mg ou placebo. RESULTADOS: Os três grupos não diferiram significativamente no que se refere às medidas eletrodérmicas nas duas sessões experimentais. Os três grupos apresentaram melhora da primeira para a segunda avaliação, com os grupos placebo e canabidiol 300mg superiores ao grupo canabidiol 600mg. CONCLUSÃO: A administração aguda de canabidiol em dose única parece não ter efeitos benéficos sobre o desempenho de pacientes com esquizofrenia no Stroop Color Word Test, embora estes dados não sejam suficientes para refutar a hipótese de que a administração continuada de canabidiol possa resultar em melhora no funcionamento cognitivo em esquizofrenia.


Subject(s)
Adult , Female , Humans , Male , Antipsychotic Agents/administration & dosage , Cannabidiol/administration & dosage , Galvanic Skin Response , Psychotic Disorders/drug therapy , Schizophrenic Psychology , Stroop Test , Analysis of Variance , Cognition/drug effects , Cognition/physiology , Dose-Response Relationship, Drug , Schizophrenia/physiopathology
8.
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo ; 59(3): 145-152, June 2004. tab
Article in English | LILACS | ID: lil-363374

ABSTRACT

Pacientes esquizofrênicos submetidos à espectroscopia de próton por ressonância magnética demonstram alterações nos níveis de N-acetilaspartato em diversas regiões cerebrais, suportando a hipótese de disfunção neuronal nestas áreas. Objetiva-se apresentar uma revisão da literatura, sobre os principais estudos de espectroscopia de próton por ressonância magnética na região frontal em esquizofrênicos. Utilizou-se o indexador MEDLINE, no período entre 1991 e março de 2004, com o cruzamento dos termos spectroscopy, schizophrenia, proton e frontal. Foram selecionados 27 artigos originais, cujos resultados mostram-se discordantes quanto à alteração nos valores de N-acetilaspartato (19 artigos apresentaram alterações nos níveis de N-acetilaspartato e oito estudos não apresentam alterações). A presente revisão sugere que esta diversidade de resultados pode ser atribuída aos seguintes fatores: 1-número de participantes; 2- variação nas características clínicas e demográficas dos grupos; 3- pouca padronização dos parâmetros de aquisição dos espectros. Os artigos que satisfazem os critérios metodológicos mais rígidos sugerem diminuição de NAA no lobo frontal de esquizofrênicos do sexo masculino.


Subject(s)
Female , Humans , Male , Aspartic Acid/analogs & derivatives , Brain Chemistry , Magnetic Resonance Spectroscopy/methods , Protons , Schizophrenia/metabolism , Aspartic Acid/analysis , Frontal Lobe/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL